Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection.

By Tamara Reyes-Robles, Francis Alonzo, L. Kozhaya, D. B. Lacy, Derya, Unutmaz, Victor J. Torres. 2013

173 citations recorded by the source corpus.

Subfields: Immunology, Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Victor J. Torres
2. Francis Alonzo
3. Tamara Reyes-Robles

In Infectious Diseases

1. Victor J. Torres
2. Francis Alonzo
3. Tamara Reyes-Robles
4. Ashira Lubkin
5. Ashley L. DuMont
6. Bo Shopsin
7. K. Lacey
8. Xuhui Zheng

Citations in the corpus

• Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5 (2016, methodology): “Toxins were purified as described previously (19, 24).”
• Staphylococcus aureus leukocidins target endothelial DARC to cause lethality in mice (2019, background): “Staphylococcus aureus leukotoxin ED targets the chemokine receptors CXCR1 and CXCR2 to kill leukocytes and promote infection.”
• Staphylococcus aureus Impairs the Function of and Kills Human Dendritic Cells via the LukAB Toxin (2019, methodology): “For experiments using bacterial supernatant as a stimulus, a 0.01% concentration of supernatant from S. aureus strain Newman, which lacks all the leukocidins and alpha-toxin (ΔΔΔΔΔ Newman; ΔlukED ΔhlgACB::tet ΔlukAB::spec Δhla::ermC) and naturally lacks PVL (59), and purified leukocidins were added ”
• Targeting leukocidin-mediated immune evasion protects mice from Staphylococcus aureus bacteremia (2020, background): “While all the leukocidins have strong tropism toward human cells, LukED and HlgAB are also active toward murine cells, thus allowing us to study the effects of these leukocidins in vivo (Alonzo et al., 2013; Lubkin et al., 2019; Reyes-Robles et al., 2013; Spaan et al., 2015, 2014).”
• Exploiting dominant‐negative toxins to combat Staphylococcus aureus pathogenesis (2016, unknown): “…in more complex and physiological settings, we first tested their inhibitory activity toward culture supernatants from the To evaluate whether the mutated leukocidins also protect from S. aureus infection, we first challenged PMNs with a S. aureus strain that lacked all the leukocidins [13].”
• Identification of biologic agents to neutralize the bicomponent leukocidins of Staphylococcus aureus (2019, result): “These findings are consistent with the observation that LukED/HlgAB and PVL/HlgCB share common receptors to target and kill hPMNs (11, 12, 15), a finding that coincides with the fact that these toxin pairs also share the greatest amino acid similarity among leukocidins (8, 9).”
• Staphylococcus aureus Leukocidin A/B (LukAB) Kills Human Monocytes via Host NLRP3 and ASC when Extracellular, but Not Intracellular (2015, methodology): “aureus Newman ΔlukAB/ΔlukED/Δhlg have been previously described [61].”
• The Bicomponent Pore-Forming Leucocidins of Staphylococcus aureus (2014, background): “Such findings are in line with the presumption that LukED (which targets CXCR2) and PVL, despite sharing a remarkable degree of sequence conservation, do not target the same receptors on host cells (199, 230).”
• Staphylococcus aureus targets the Duffy antigen receptor for chemokines (DARC) to lyse erythrocytes (2015, background): “The affinity of the binding components HlgA and LukE for DARC is lower than their myeloid receptors, CXCR1 and CXCR2 (Reyes-Robles et al., 2013; Spaan et al., 2014).”